SG10201801326PA - Non-human animals having a humanized signal-regulatory protein gene - Google Patents

Non-human animals having a humanized signal-regulatory protein gene

Info

Publication number
SG10201801326PA
SG10201801326PA SG10201801326PA SG10201801326PA SG10201801326PA SG 10201801326P A SG10201801326P A SG 10201801326PA SG 10201801326P A SG10201801326P A SG 10201801326PA SG 10201801326P A SG10201801326P A SG 10201801326PA SG 10201801326P A SG10201801326P A SG 10201801326PA
Authority
SG
Singapore
Prior art keywords
protein gene
human animals
regulatory protein
humanized
signal
Prior art date
Application number
SG10201801326PA
Inventor
Andrew J Murphy
O Gavin Thurston
Bindu Varghese
Cagan Gurer
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG10201801326PA publication Critical patent/SG10201801326PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027New breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Humanized animals, e.g. knockin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/12Animals modified by administration of exogenous cells
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/15Humanized animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/054Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/072Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/01Animal expressing industrially exogenous proteins
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0331Animal model for proliferative diseases
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/035Animal model for multifactorial diseases
    • A01K2267/0381Animal model for diseases of the hematopoietic system
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/035Animal model for multifactorial diseases
    • A01K2267/0387Animal model for diseases of the immune system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C12N2015/8572Animal models for proliferative diseases, e.g. comprising an oncogene
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/30Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/03Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048Protein-tyrosine-phosphatase (3.1.3.48)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells
SG10201801326PA 2013-09-23 2014-09-23 Non-human animals having a humanized signal-regulatory protein gene SG10201801326PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361881261P 2013-09-23 2013-09-23

Publications (1)

Publication Number Publication Date
SG10201801326PA true SG10201801326PA (en) 2018-03-28

Family

ID=51663510

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201801326PA SG10201801326PA (en) 2013-09-23 2014-09-23 Non-human animals having a humanized signal-regulatory protein gene
SG11201601184UA SG11201601184UA (en) 2013-09-23 2014-09-23 Non-human animals having a humanized signal-regulatory protein gene
SG10201902547SA SG10201902547SA (en) 2013-09-23 2014-09-23 Non-human animals having a humanized signal-regulatory protein gene

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG11201601184UA SG11201601184UA (en) 2013-09-23 2014-09-23 Non-human animals having a humanized signal-regulatory protein gene
SG10201902547SA SG10201902547SA (en) 2013-09-23 2014-09-23 Non-human animals having a humanized signal-regulatory protein gene

Country Status (28)

Country Link
US (9) US9193977B2 (en)
EP (4) EP4269430A3 (en)
JP (4) JP6453893B2 (en)
KR (2) KR102407354B1 (en)
CN (2) CN105592695B (en)
AU (2) AU2014321187B2 (en)
CA (1) CA2925564C (en)
CY (1) CY1121410T1 (en)
DK (3) DK2922394T3 (en)
ES (3) ES2959333T3 (en)
FI (1) FI3434101T3 (en)
HK (1) HK1209275A1 (en)
HR (2) HRP20231121T1 (en)
HU (2) HUE042412T2 (en)
IL (4) IL297607B2 (en)
LT (2) LT3434101T (en)
MX (1) MX368931B (en)
NZ (1) NZ717817A (en)
PH (1) PH12016500342A1 (en)
PL (2) PL3434101T3 (en)
PT (3) PT3434101T (en)
RS (2) RS64573B1 (en)
RU (2) RU2018136614A (en)
SG (3) SG10201801326PA (en)
SI (2) SI3434101T1 (en)
TR (1) TR201901782T4 (en)
WO (1) WO2015042557A1 (en)
ZA (1) ZA201601138B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541646B2 (en) 2009-10-06 2013-09-24 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
RU2730643C2 (en) 2011-02-15 2020-08-24 Ридженерон Фармасьютикалз, Инк. Humanised m-csf mice
AU2013312359B8 (en) 2012-09-07 2019-08-15 Institute For Research In Biomedicine (Irb) Genetically modified non-human animals and methods of use thereof
RU2673156C2 (en) 2012-11-05 2018-11-22 Ридженерон Фармасьютикалз, Инк. Genetically modified non-human animals and methods for use thereof
LT3434101T (en) 2013-09-23 2023-09-25 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized signal-regulatory protein gene
NZ718655A (en) 2013-10-15 2022-08-26 Regeneron Pharma Humanized il-15 animals
MX2016013241A (en) 2014-04-08 2017-05-03 Regeneron Pharma Non-human animals having humanized fc-gamma receptors.
NO2785538T3 (en) 2014-05-07 2018-08-04
CN113045639A (en) 2014-05-19 2021-06-29 再生元制药公司 Genetically modified non-human animals expressing human EPO
ES2783424T3 (en) 2014-06-19 2020-09-17 Regeneron Pharma Non-human animals that have a humanized programmed cell death gene 1
RU2726446C2 (en) 2014-11-24 2020-07-14 Регенерон Фармасьютикалз, Инк. Non-human animals expressing humanised complex cd3
PT3850946T (en) 2014-12-05 2024-01-02 Regeneron Pharma Non-human animals having a humanized cluster of differentiation 47 gene
IL254727B2 (en) * 2015-04-13 2023-10-01 Regeneron Pharma Humanized sirpa-il15 knockin mice and methods of use thereof
CN104904661B (en) * 2015-06-05 2018-07-24 杭州正因生物技术有限公司 A kind of humanization mouse
IL256989B (en) 2015-08-07 2022-08-01 Alx Oncology Inc Constructs having a sirp-alpha domain or variant thereof
CA3003786C (en) 2015-11-20 2023-09-12 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3
ES2908669T3 (en) 2016-02-04 2022-05-03 Regeneron Pharma Non-human animals that have a genetically modified ANGPTL8 gene
CN109068621B (en) 2016-02-29 2021-07-20 再生元制药公司 Rodent with humanized TMPRSS gene
WO2018177441A1 (en) * 2017-03-31 2018-10-04 Beijing Biocytogen Co., Ltd GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα
CN108588126B (en) 2017-03-31 2020-04-10 北京百奥赛图基因生物技术有限公司 Preparation method and application of humanized modified animal model of CD47 gene
WO2018233608A1 (en) * 2017-06-19 2018-12-27 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric cd28
CN109136261B (en) 2017-06-19 2021-03-16 百奥赛图(北京)医药科技股份有限公司 Preparation method and application of humanized CD28 gene modified animal model
CA3067872A1 (en) 2017-07-31 2019-02-07 Regeneron Pharmaceuticals, Inc. Cas-transgenic mouse embryonic stem cells and mice and uses thereof
CA3068072A1 (en) 2017-07-31 2019-02-07 Regeneron Pharmaceuticals, Inc. Methods and compositions for assessing crispr/cas-mediated disruption or excision and crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo
MX2020003589A (en) * 2017-09-29 2020-07-22 Regeneron Pharma Non-human animals comprising a humanized.
AU2018375796A1 (en) 2017-11-30 2020-04-23 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized TRKB locus
KR20240038811A (en) 2018-03-19 2024-03-25 리제너론 파마슈티칼스 인코포레이티드 Transcription modulation in animals using crispr/cas systems
US11576984B2 (en) 2018-03-26 2023-02-14 Regeneron Pharmaceuticals, Inc. Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes and method of using
KR20210031868A (en) 2018-07-16 2021-03-23 리제너론 파마슈티칼스 인코포레이티드 Non-human animal model of DITRA disease and uses thereof
WO2020160285A1 (en) * 2019-02-01 2020-08-06 The Board Of Trustees Of The Leland Stanford Junior University SIRPα EXPRESSION ON T CELLS IS A BIOMARKER FOR FUNCTIONAL T CELLS DURING EXHAUSTION
US11737435B2 (en) 2019-04-04 2023-08-29 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized coagulation factor 12 locus
BR112021024003A2 (en) 2019-05-31 2022-04-19 Alx Oncology Inc Cancer treatment methods with sirp alpha-fc fusion in combination with an immune checkpoint inhibitor
EP3801011A1 (en) 2019-06-04 2021-04-14 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
MX2021015122A (en) 2019-06-07 2022-04-06 Regeneron Pharma Non-human animals comprising a humanized albumin locus.
CN113122574A (en) * 2019-12-31 2021-07-16 百奥赛图(北京)医药科技股份有限公司 Construction method of immunodeficiency humanized non-human animal
EP4138550A1 (en) 2020-04-21 2023-03-01 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cxcl13 gene
KR20230124973A (en) 2020-12-21 2023-08-28 리제너론 파마슈티칼스 인코포레이티드 Non-human animals having a humanized TSLP gene, a humanized TSLP receptor gene, and/or a humanized IL7RA gene
CN115997729A (en) * 2022-01-25 2023-04-25 百奥赛图江苏基因生物技术有限公司 NKP46 gene humanized non-human animal and construction method and application thereof
US20240102045A1 (en) 2022-07-19 2024-03-28 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2024073679A1 (en) 2022-09-29 2024-04-04 Regeneron Pharmaceuticals, Inc. Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149635A (en) 1986-09-12 1992-09-22 Abbott Biotech, Inc. Messenger RNA stabilization in animal cells
CZ294615B6 (en) * 1997-09-12 2005-02-16 Apotech R & D Sa Medicament containing antibodies that are reactive to APRIL polypeptide ligand intended for treating cancer
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2364335T3 (en) * 2003-12-24 2011-08-31 G2 Inflammation Pty Ltd TRANSGENIC NON-HUMAN MAMMER THAT INCLUDES A POLINUCLEOTIDE CODIFYING HUMAN OR HUMANIZED C5AR.
DK1802193T3 (en) 2004-10-19 2014-06-10 Regeneron Pharma Method of producing a homozygous mouse for genetic modification
EP1907566A4 (en) * 2005-05-27 2008-12-10 Memory Pharm Corp Transgenic alzheimer's mouse model vectors and uses thereof
US20070028316A1 (en) 2005-06-02 2007-02-01 Xiaoxia Li Transgenic non-human Act1-deficient mammals and uses thereof
JP2011500005A (en) * 2007-10-11 2011-01-06 ユニバーシティー ヘルス ネットワーク Modulation of SIRPα-CD47 interaction to increase human hematopoietic stem cell engraftment and compounds therefor
WO2009114400A1 (en) 2008-03-07 2009-09-17 Regeneron Pharmaceuticals, Inc. Es cell-derived mice from diploid host embryo injection
RU2425880C2 (en) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Method of producing transgene mice
US8541646B2 (en) 2009-10-06 2013-09-24 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
US9402377B2 (en) * 2010-09-20 2016-08-02 Yale University Human SIRPAalpha transgenic animals and their methods of use
WO2012112586A1 (en) * 2011-02-14 2012-08-23 Revivicor, Inc. Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
RU2730643C2 (en) * 2011-02-15 2020-08-24 Ридженерон Фармасьютикалз, Инк. Humanised m-csf mice
EP3262932B1 (en) 2011-10-28 2019-05-15 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
HUE048511T2 (en) 2011-10-28 2020-07-28 Regeneron Pharma Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
RS53683B1 (en) 2011-10-28 2015-04-30 Regeneron Pharmaceuticals Inc. Humanized il-6 and il-6 receptor
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
AU2013312359B8 (en) 2012-09-07 2019-08-15 Institute For Research In Biomedicine (Irb) Genetically modified non-human animals and methods of use thereof
RU2673156C2 (en) 2012-11-05 2018-11-22 Ридженерон Фармасьютикалз, Инк. Genetically modified non-human animals and methods for use thereof
CN111484999A (en) 2013-02-20 2020-08-04 瑞泽恩制药公司 Humanized T cell co-receptor mice
EP2958937B1 (en) 2013-02-22 2018-08-15 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
LT3434101T (en) 2013-09-23 2023-09-25 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized signal-regulatory protein gene
CA2984413A1 (en) 2015-04-30 2016-11-03 Institute Of Immunology Co., Ltd. Transgenic non-human animal expressing human specific molecule and human fc.gamma. receptor family

Also Published As

Publication number Publication date
RS64573B1 (en) 2023-10-31
US20210251201A1 (en) 2021-08-19
NZ717817A (en) 2022-07-01
US20160374321A1 (en) 2016-12-29
HUE063376T2 (en) 2024-01-28
EP2922394B1 (en) 2017-02-22
EP4269430A3 (en) 2024-01-10
WO2015042557A1 (en) 2015-03-26
CN108441497B (en) 2021-10-29
RS58365B1 (en) 2019-03-29
ES2959333T3 (en) 2024-02-23
EP2922394A1 (en) 2015-09-30
ES2710282T3 (en) 2019-04-24
KR102370419B1 (en) 2022-03-04
KR102407354B1 (en) 2022-06-10
HK1209275A1 (en) 2016-04-01
MX2016003636A (en) 2016-07-21
US11019810B2 (en) 2021-06-01
IL278679B2 (en) 2023-04-01
IL262958A (en) 2018-12-31
JP6453893B2 (en) 2019-01-16
US20160050896A1 (en) 2016-02-25
CA2925564A1 (en) 2015-03-26
JP6875573B2 (en) 2021-05-26
IL244187B (en) 2018-11-29
PT3175706T (en) 2019-02-11
CN105592695B (en) 2018-04-10
TR201901782T4 (en) 2019-03-21
JP2020114209A (en) 2020-07-30
US20190124895A1 (en) 2019-05-02
IL278679A (en) 2022-12-01
DK2922394T3 (en) 2017-05-15
US9700027B2 (en) 2017-07-11
PL3434101T3 (en) 2024-02-19
JP2021104064A (en) 2021-07-26
DK3434101T3 (en) 2023-10-02
SG11201601184UA (en) 2016-03-30
EP3175706B1 (en) 2018-11-07
KR20160056900A (en) 2016-05-20
PT2922394T (en) 2017-05-22
JP6665269B2 (en) 2020-03-13
IL297607B2 (en) 2024-01-01
RU2018136614A (en) 2018-11-27
EP3434101A1 (en) 2019-01-30
SI3175706T1 (en) 2019-03-29
CN105592695A (en) 2016-05-18
IL297607A (en) 2022-12-01
EP4269430A2 (en) 2023-11-01
JP2016537015A (en) 2016-12-01
PL3175706T3 (en) 2019-05-31
CA2925564C (en) 2023-03-21
PT3434101T (en) 2023-09-19
FI3434101T3 (en) 2023-10-02
HUE042412T2 (en) 2019-06-28
WO2015042557A4 (en) 2015-06-18
US20180139941A1 (en) 2018-05-24
HRP20231121T1 (en) 2023-12-22
KR20220032125A (en) 2022-03-15
ES2624614T3 (en) 2017-07-17
PH12016500342A1 (en) 2016-05-02
LT3175706T (en) 2019-02-25
US20200187468A1 (en) 2020-06-18
US20170265442A1 (en) 2017-09-21
RU2016110462A3 (en) 2018-03-30
EP3175706A1 (en) 2017-06-07
DK3175706T3 (en) 2019-03-04
US20150089679A1 (en) 2015-03-26
US9901083B2 (en) 2018-02-27
EP3434101B1 (en) 2023-08-16
JP7149370B2 (en) 2022-10-06
US9127292B2 (en) 2015-09-08
US20150089678A1 (en) 2015-03-26
IL297607B1 (en) 2023-09-01
ZA201601138B (en) 2020-06-24
US10206379B2 (en) 2019-02-19
LT3434101T (en) 2023-09-25
RU2671166C2 (en) 2018-10-29
US9462794B2 (en) 2016-10-11
MX368931B (en) 2019-10-22
IL244187A0 (en) 2016-04-21
RU2016110462A (en) 2017-10-30
CN108441497A (en) 2018-08-24
JP2019047818A (en) 2019-03-28
AU2014321187B2 (en) 2020-09-17
CY1121410T1 (en) 2020-05-29
US9193977B2 (en) 2015-11-24
SI3434101T1 (en) 2023-11-30
AU2020286187A1 (en) 2021-01-07
US10426146B2 (en) 2019-10-01
SG10201902547SA (en) 2019-04-29
HRP20190227T1 (en) 2019-06-14

Similar Documents

Publication Publication Date Title
IL262958A (en) Non-human animals having a humanized signal-regulatory protein gene
IL269907B (en) Humanized il-15 animals
HK1223505A1 (en) Non-human animals having a humanized -cell activating factor gene
HK1223504A1 (en) Non-human animals having a humanized a proliferation-inducing ligand gene
HK1220990A1 (en) Lincrna-deficient non-human animals lincrna
HK1212552A1 (en) Gene knock-in non-human animal
HUE046602T2 (en) Automated milking stall
ZA201801103B (en) Non-human animals having a humanized signal-regulatory protein gene